ArticleCureus2025
Linac-Based Radiosurgery Treatment for a Pineal Parenchymal Tumor.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pineal parenchymal tumors (PPTs) are uncommon in general and rare in the adult population. Currently, the optimal treatment for PPT of intermediate differentiation (PPTID) in older patients is unknown. Stereotactic radiosurgery (SRS) has been used as both primary and adjuvant therapy, with single or fractionated doses using Gamma Knife (Elekta, Stockholm, Sweden) or CyberKnife (Accuray Inc., Madison, WI). This article presents the case of a 77-year-old woman with a biopsy-confirmed PPTID. She was treated with single fraction VMAT (volumetric modulated arc therapy)-based SRS on a Varian TrueBeam Edge linac (Varian Medical Systems, Palo Alto, CA) using multiple non-coplanar arcs. Contouring and treatment planning were performed on contrast-enhanced MRI and CT images. Accurate patient set-up and immobilization were achieved with an open-faced thermoplastic mask, real-time motion management using an optical surface monitoring system, and kV CBCT prior to each arc. The patient has shown excellent response for tumor size with frequent follow-up up to 84 months, but 25 months later developed double-vision and headaches with MRI revealing decreasing tumor size but enhancement and FLAIR changes in the adjacent brain parenchyma suggestive of radiation necrosis. These changes stabilized as of 32 months of follow-up, and then started to decrease by 35 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.